Developer docs
API playgroundTry for free, no card

Search company profiles

Parse Biosciences

Full company profile

uuid000037q

Namestring
Parse Biosciences
Legal namestring
Parse Biosciences
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Parse Biosciences, founded in 2018 and headquartered in Seattle, develops scalable single-cell RNA sequencing solutions built on its proprietary Evercode™ split-pool combinatorial barcoding technology. The platform fixes and permeabilizes cells so they serve as their own reaction vessels, eliminating the need for microfluidic instruments or microwell arrays and enabling experiments from 10,000 to 5 million cells per run. The Evercode product family spans whole-transcriptome kits (WT Mini, WT, WT Mega, WT Penta, WT FFPE), immune profiling kits (TCR, BCR), fixation modules, CRISPR Detect pooled screens, and a Gene Select targeted panel; the GigaLab service tier delivers large-scale projects (10M+ cells) for AI-driven drug discovery customers such as Tahoe Therapeutics and Graph Therapeutics. The free Trailmaker cloud platform guides users from FASTQ files through publication-ready figures with native Seurat and Scanpy export.

The company sells through direct/website channels, a growing authorized distributor network, and service providers across 40+ countries, serving academic institutions, biotech, and pharmaceutical R&D organizations with a quote-based kit-plus-services model. As of December 2025, Parse was acquired by QIAGEN N.V. for approximately $225 million in cash (up to $280 million with milestones), with QIAGEN projecting approximately $40 million in 2026 sales contribution from the Parse business. Prior to the acquisition, the company had raised over $100 million across a Series B ($41.5M, 2022) led by Marshall Wace and Janus Henderson and a Series C ($50M, 2023) led by Soleus Capital, and had grown to serve 3,000+ labs. Following the acquisition, the Parse CEO departed and the brand operates as a subsidiary within QIAGEN's Sample technologies portfolio.

Short descriptiontext

Parse Biosciences is a Seattle-based life sciences tools company that builds instrument-free single-cell RNA sequencing kits and services based on its proprietary Evercode split-pool combinatorial barcoding technology, serving 3,000+ academic, biotech, and pharmaceutical research labs across 40+ countries; the company was acquired by QIAGEN in December 2025 for approximately $225 million.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single cell sequencing, single cell RNA-seq, combinatorial barcoding, immune profiling kits, scRNA-seq analysis software
Industry1 code
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Single Cell Sequencing Reagents
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Evercode Kit Products
TypeOne Time License
Description

Sale of single cell sequencing reagent kits including Evercode WT Mini, WT, WT Mega, WT Penta, TCR, BCR, Fixation, Gene Select, and CRISPR Detect. Land-and-expand model as labs scale from small to large throughput kits.

parsebiosciences.com
2GigaLab Services
TypeProfessional Services
Description

Large-scale single cell sequencing services for projects requiring 10M+ cells. Provides sequencing services using the GigaLab platform for drug discovery and AI-driven research.

parsebiosciences.com
3Trailmaker Platform
TypeSubscription Recurring
Description

Free analysis platform included with kits. Provides end-to-end workflow from FASTQ files through publication-ready figures.

parsebiosciences.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Evercode
Description

Scalable single cell sequencing technology platform using combinatorial barcoding, available in multiple formats including Whole Transcriptome, TCR, BCR, and FFPE variants.

parsebiosciences.com
+2 more records
Core offering1 text field

Parse Biosciences develops and sells instrument-free single cell RNA sequencing reagent kits built on its proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio spans entry-level to ultra-high-throughput whole transcriptome kits, paired TCR/BCR immune profiling kits, fixation/sample preservation kits, and FFPE-compatible kits, complemented by GigaLab services for 10M+ cell projects and the Trailmaker cloud-based data analysis software.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 27.5% more transcripts per cell detected vs Chromium GEM-X at 40,000 reads/cell
+5 more records
Product overview1 text field

Parse Biosciences offers a comprehensive single cell sequencing platform based on proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio centers on instrument-free single cell solutions ranging from entry-level (Evercode WT Mini, 10K cells) to ultra-high-throughput (Evercode WT Penta, 5M cells) whole transcriptome kits. Specialized immune profiling products include Evercode TCR and Evercode BCR for paired receptor sequencing. Supporting add-on modules include Gene Select for targeted panels, CRISPR Detect for pooled screens, Evercode Fixation for sample preservation, and Evercode Whole Blood Fixation for blood samples. FFPE-compatible Evercode WT FFPE enables analysis of archived tissue. The GigaLab service offering enables single cell sequencing at 10M+ cell scale. Trailmaker cloud platform provides end-to-end data analysis with integrated visualization and export to Seurat/Scanpy. The platform is sold directly and through a growing distributor network globally, with over 3,000 labs served. Parse was acquired by QIAGEN in late 2025.

Product and service1 record
1Evercode WT Mini
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Landmark alliance combining massively parallel single cell perturbation with bit.bio's cell programming to build foundational map of transcription factor-driven cell fate. Alliance powers AI-driven predictive medicine and human cell manufacturing by linking genetic inputs to cellular outputs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

Strategic partnership to create one of the largest immune cell perturbation atlases. Combines Graph's lab-in-the-loop AI platform with Parse's GigaLab single cell technology to profile hundreds of millions of cells from patients with immune diseases. Aims to accelerate AI-first drug discovery by revealing diverse immune and tissue interactions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-19
Description

Collaboration to develop a platform combining Codebreaker's synthetic biology variant engineering capabilities with Parse's Evercode single cell technology. Enables parallel testing of thousands of genetic variants at single cell resolution to generate causal data for rare and private variants that traditional observational studies cannot analyze.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-11
Description

Parse provides GigaLab single cell sequencing services for Tahoe Therapeutics' 300 million cell project to generate the largest perturbation-focused single cell dataset for AI-driven drug discovery. Project aims to train AI algorithms with unprecedented scale.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-12-01
Description

QIAGEN acquired Parse Biosciences in December 2025 for approximately $225 million in cash, with potential milestone payments up to $280 million total. The acquisition strengthens QIAGEN's Sample technologies portfolio into highly scalable single-cell solutions. Parse operates as a QIAGEN company while maintaining its brand identity.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Collaboration with stealth Third Rock Ventures-backed company developing precision medicines for autoimmune disease. Uses Parse's GigaLab platform to create large atlas of 5 million T cell receptors (TCRs) to enhance understanding of autoimmune illnesses and accelerate drug discovery.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-14
Description

Expanding presence in international markets including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea through distribution partnerships to meet increasing demand from global research markets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

The dominant player in single-cell sequencing with the Chromium droplet-based platform. Direct competitor to Parse's Evercode technology, with the largest installed base of instruments in academic and pharma research labs. Parse's marketing materials explicitly position Evercode against Chromium with head-to-head sensitivity and multiplet rate comparisons.

TypeDirect peer
Description

Offers the BD Rhapsody single-cell analysis system, a competing platform to Parse's Evercode using a different microwell-based barcoding approach. Targets similar academic and translational research customers and is referenced in Parse's competitive comparisons.

TypeDirect peer
Description

Long-standing player in single-cell genomics with the C1 and Hyperion imaging mass cytometry platforms. Operates in adjacent single-cell analysis segments and serves similar academic research customers, though at smaller scale than 10x or Parse.

TypeBroad incumbent
Description

Dominant sequencing platform provider whose instruments are used downstream of Parse's library prep kits. While not a direct single-cell library prep competitor, Illumina's strategic moves in library prep and partnerships with other single-cell companies affect Parse's market dynamics and sequencer compatibility.

TypeBroad incumbent
Description

Provides reagents, kits, and analytical tools for life science research including single-cell workflows. Overlaps with Parse through the consumables and reagent product category, particularly in proteomics-adjacent single-cell applications.

TypeEmerging player
Description

Single-cell genomics platform focused on DNA-level analysis (Tapestri), particularly for oncology applications and clonal heterogeneity. Competes in adjacent single-cell use cases (DNA rather than RNA) and serves similar translational research customers.

TypeEmerging player
Description

Spatial biology company offering single-cell resolution tissue analysis. Adjacent to Parse's single-cell RNA sequencing business, with overlap in immuno-oncology and translational research customer segments.

TypeBroad incumbent
Description

Parent company of Parse following the December 2025 acquisition. Offers sample technologies, NGS library prep, and bioinformatics for molecular biology. Provides global distribution, customer relationships, and complementary products that will accelerate Parse's commercial reach.

TypeEmerging player
Description

Sequencing platform provider whose UG100 instrument is used in Parse's GigaLab workflows. Currently a technology partner, but a potential competitive threat if Ultima develops native single-cell library prep capabilities or expands into upstream sample prep.

TypeEmerging player
Description

Following its acquisition of NanoString, Bruker offers spatial transcriptomics and single-cell analysis solutions (CosMx, GeoMx). Competes in adjacent single-cell and tissue analysis markets with overlap in academic and translational research customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Parse Biosciences

Single Cell Sequencing Reagentsparsebiosciences.com

Parse Biosciences is a Seattle-based life sciences tools company that builds instrument-free single-cell RNA sequencing kits and services based on its proprietary Evercode split-pool combinatorial barcoding technology, serving 3,000+ academic, biotech, and pharmaceutical research labs across 40+ countries; the company was acquired by QIAGEN in December 2025 for approximately $225 million.

What Parse Biosciences does

Parse Biosciences, founded in 2018 and headquartered in Seattle, develops scalable single-cell RNA sequencing solutions built on its proprietary Evercode™ split-pool combinatorial barcoding technology. The platform fixes and permeabilizes cells so they serve as their own reaction vessels, eliminating the need for microfluidic instruments or microwell arrays and enabling experiments from 10,000 to 5 million cells per run. The Evercode product family spans whole-transcriptome kits (WT Mini, WT, WT Mega, WT Penta, WT FFPE), immune profiling kits (TCR, BCR), fixation modules, CRISPR Detect pooled screens, and a Gene Select targeted panel; the GigaLab service tier delivers large-scale projects (10M+ cells) for AI-driven drug discovery customers such as Tahoe Therapeutics and Graph Therapeutics. The free Trailmaker cloud platform guides users from FASTQ files through publication-ready figures with native Seurat and Scanpy export.

The company sells through direct/website channels, a growing authorized distributor network, and service providers across 40+ countries, serving academic institutions, biotech, and pharmaceutical R&D organizations with a quote-based kit-plus-services model. As of December 2025, Parse was acquired by QIAGEN N.V. for approximately $225 million in cash (up to $280 million with milestones), with QIAGEN projecting approximately $40 million in 2026 sales contribution from the Parse business. Prior to the acquisition, the company had raised over $100 million across a Series B ($41.5M, 2022) led by Marshall Wace and Janus Henderson and a Series C ($50M, 2023) led by Soleus Capital, and had grown to serve 3,000+ labs. Following the acquisition, the Parse CEO departed and the brand operates as a subsidiary within QIAGEN's Sample technologies portfolio.

Parse Biosciences firmographics

Firmographics
Name
Parse Biosciences
Legal name
Parse Biosciences
Website
https://parsebiosciences.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
101–250 employees
Short description
Parse Biosciences is a Seattle-based life sciences tools company that builds instrument-free single-cell RNA sequencing kits and services based on its proprietary Evercode split-pool combinatorial barcoding technology, serving 3,000+ academic, biotech, and pharmaceutical research labs across 40+ countries; the company was acquired by QIAGEN in December 2025 for approximately $225 million.
Ownership category
akta.pro rank

Parse Biosciences industry classification

Industry
Product category
Single Cell Sequencing Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Single cell sequencing
  • Single cell RNA-seq
  • Combinatorial barcoding
  • Immune profiling kits
  • ScRNA-seq analysis software

Where Parse Biosciences is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Parse Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Evercode Kit Products: Sale of single cell sequencing reagent kits including Evercode WT Mini, WT, WT Mega, WT Penta, TCR, BCR, Fixation, Gene Select, and CRISPR Detect. Land-and-expand model as labs scale from small to large throughput kits.
  2. GigaLab Services: Large-scale single cell sequencing services for projects requiring 10M+ cells. Provides sequencing services using the GigaLab platform for drug discovery and AI-driven research.
  3. Trailmaker Platform: Free analysis platform included with kits. Provides end-to-end workflow from FASTQ files through publication-ready figures.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Parse Biosciences product offering

Product offering

Core offering

Parse Biosciences develops and sells instrument-free single cell RNA sequencing reagent kits built on its proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio spans entry-level to ultra-high-throughput whole transcriptome kits, paired TCR/BCR immune profiling kits, fixation/sample preservation kits, and FFPE-compatible kits, complemented by GigaLab services for 10M+ cell projects and the Trailmaker cloud-based data analysis software.

Product overview

Parse Biosciences offers a comprehensive single cell sequencing platform based on proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio centers on instrument-free single cell solutions ranging from entry-level (Evercode WT Mini, 10K cells) to ultra-high-throughput (Evercode WT Penta, 5M cells) whole transcriptome kits. Specialized immune profiling products include Evercode TCR and Evercode BCR for paired receptor sequencing. Supporting add-on modules include Gene Select for targeted panels, CRISPR Detect for pooled screens, Evercode Fixation for sample preservation, and Evercode Whole Blood Fixation for blood samples. FFPE-compatible Evercode WT FFPE enables analysis of archived tissue. The GigaLab service offering enables single cell sequencing at 10M+ cell scale. Trailmaker cloud platform provides end-to-end data analysis with integrated visualization and export to Seurat/Scanpy. The platform is sold directly and through a growing distributor network globally, with over 3,000 labs served. Parse was acquired by QIAGEN in late 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • Evercode: Scalable single cell sequencing technology platform using combinatorial barcoding, available in multiple formats including Whole Transcriptome, TCR, BCR, and FFPE variants.
  • GigaLab
  • Trailmaker

Products and services

  • Evercode WT Mini

Quantifiable outcome

  • 27.5% more transcripts per cell detected vs Chromium GEM-X at 40,000 reads/cell
  • +5 more outcomes

Companies that use Parse Biosciences

Customer profile

Named customers20 records

Segments3 records

Ideal customer profiles3 records

Parse Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

Parse Biosciences partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

  • bit.biocoreStrategic or Co-development Partner · 27 May 2026Landmark alliance combining massively parallel single cell perturbation with bit.bio's cell programming to build foundational map of transcription factor-driven cell fate. Alliance powers AI-driven predictive medicine and human cell manufacturing by linking genetic inputs to cellular outputs.
  • Graph TherapeuticscoreStrategic or Co-development Partner · 21 January 2026Strategic partnership to create one of the largest immune cell perturbation atlases. Combines Graph's lab-in-the-loop AI platform with Parse's GigaLab single cell technology to profile hundreds of millions of cells from patients with immune diseases. Aims to accelerate AI-first drug discovery by revealing diverse immune and tissue interactions.
  • Codebreaker LabscoreStrategic or Co-development Partner · 19 December 2025Collaboration to develop a platform combining Codebreaker's synthetic biology variant engineering capabilities with Parse's Evercode single cell technology. Enables parallel testing of thousands of genetic variants at single cell resolution to generate causal data for rare and private variants that traditional observational studies cannot analyze.
  • Tahoe TherapeuticscoreStrategic or Co-development Partner · 11 December 2025Parse provides GigaLab single cell sequencing services for Tahoe Therapeutics' 300 million cell project to generate the largest perturbation-focused single cell dataset for AI-driven drug discovery. Project aims to train AI algorithms with unprecedented scale.
  • QIAGENflagshipOEM/ Whitelabel/ Licensing Partner · 1 December 2025QIAGEN acquired Parse Biosciences in December 2025 for approximately $225 million in cash, with potential milestone payments up to $280 million total. The acquisition strengthens QIAGEN's Sample technologies portfolio into highly scalable single-cell solutions. Parse operates as a QIAGEN company while maintaining its brand identity.
  • Third Rock Ventures-backed CompanyminorStrategic or Co-development Partner · 13 November 2025Collaboration with stealth Third Rock Ventures-backed company developing precision medicines for autoimmune disease. Uses Parse's GigaLab platform to create large atlas of 5 million T cell receptors (TCRs) to enhance understanding of autoimmune illnesses and accelerate drug discovery.
  • International Research PartnersminorChannel Partner/ Reseller/ Distributor · 14 December 2023Expanding presence in international markets including Australia, Europe, India, Israel, New Zealand, Singapore, and South Korea through distribution partnerships to meet increasing demand from global research markets.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Parse Biosciences competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: The dominant player in single-cell sequencing with the Chromium droplet-based platform. Direct competitor to Parse's Evercode technology, with the largest installed base of instruments in academic and pharma research labs. Parse's marketing materials explicitly position Evercode against Chromium with head-to-head sensitivity and multiplet rate comparisons.
  • BD (Becton Dickinson): Offers the BD Rhapsody single-cell analysis system, a competing platform to Parse's Evercode using a different microwell-based barcoding approach. Targets similar academic and translational research customers and is referenced in Parse's competitive comparisons.
  • Standard BioTools (formerly Fluidigm): Long-standing player in single-cell genomics with the C1 and Hyperion imaging mass cytometry platforms. Operates in adjacent single-cell analysis segments and serves similar academic research customers, though at smaller scale than 10x or Parse.

Broad incumbents

  • Illumina: Dominant sequencing platform provider whose instruments are used downstream of Parse's library prep kits. While not a direct single-cell library prep competitor, Illumina's strategic moves in library prep and partnerships with other single-cell companies affect Parse's market dynamics and sequencer compatibility.
  • Bio-Techne: Provides reagents, kits, and analytical tools for life science research including single-cell workflows. Overlaps with Parse through the consumables and reagent product category, particularly in proteomics-adjacent single-cell applications.
  • QIAGEN: Parent company of Parse following the December 2025 acquisition. Offers sample technologies, NGS library prep, and bioinformatics for molecular biology. Provides global distribution, customer relationships, and complementary products that will accelerate Parse's commercial reach.

Emerging players

  • Mission Bio: Single-cell genomics platform focused on DNA-level analysis (Tapestri), particularly for oncology applications and clonal heterogeneity. Competes in adjacent single-cell use cases (DNA rather than RNA) and serves similar translational research customers.
  • Akoya Biosciences: Spatial biology company offering single-cell resolution tissue analysis. Adjacent to Parse's single-cell RNA sequencing business, with overlap in immuno-oncology and translational research customer segments.
  • Ultima Genomics: Sequencing platform provider whose UG100 instrument is used in Parse's GigaLab workflows. Currently a technology partner, but a potential competitive threat if Ultima develops native single-cell library prep capabilities or expands into upstream sample prep.
  • Bruker (NanoString spatial biology): Following its acquisition of NanoString, Bruker offers spatial transcriptomics and single-cell analysis solutions (CosMx, GeoMx). Competes in adjacent single-cell and tissue analysis markets with overlap in academic and translational research customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Parse Biosciences social profiles

Digital presence

Parse Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Parse Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Parse Biosciences funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Parse Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parse Biosciences

What does Parse Biosciences do?

Parse Biosciences develops and sells instrument-free single cell RNA sequencing reagent kits built on its proprietary Evercode split-pool combinatorial barcoding technology. The product portfolio spans entry-level to ultra-high-throughput whole transcriptome kits, paired TCR/BCR immune profiling kits, fixation/sample preservation kits, and FFPE-compatible kits, complemented by GigaLab services for 10M+ cell projects and the Trailmaker cloud-based data analysis software.

Is Parse Biosciences a public or private company?

Parse Biosciences is a private company. It is classified as corporate owned and is currently acquired.

When was Parse Biosciences founded?

Parse Biosciences was founded in 2019. It employs 101 to 250 people.

Where is Parse Biosciences based?

Parse Biosciences is headquartered in Seattle, United States, in the North America region.

How does Parse Biosciences make money?

Three revenue lines are on record. Evercode Kit Products are the primary driver. The others are gigaLab Services and trailmaker Platform.

Who are Parse Biosciences's main competitors?

Direct peers on record are 10x Genomics, BD (Becton Dickinson) and Standard BioTools (formerly Fluidigm). Broad incumbents are Illumina, Bio-Techne and QIAGEN. Emerging players are Mission Bio, Akoya Biosciences, Ultima Genomics and Bruker (NanoString spatial biology).

Does Parse Biosciences have an API?

No public API is recorded for Parse Biosciences.

What industry is Parse Biosciences in?

Parse Biosciences's product category is Single Cell Sequencing Reagents. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Machine MakerParse Biosciences and Nomic Bio Partner to Develop 100 Million-Cell AI-Ready Dataset for Immune BiologyParse Biosciences and Nomic Bio partnered to develop Cascade, a dataset of 100 million cells combining single-cell RNA-seq and proteomic secretome profiles. The dataset will capture immune responses to over 150,000 cytokine and drug conditions, aiming to improve AI models for drug discovery. Leading pharma companies have committed to foundational partnerships.Genengnews100 Million-Cell AI-Ready Dataset with Single-Cell and Proteomic Data Created by Parse and NomicParse Biosciences and Nomic Bio announced a partnership to create Cascade, a 100-million-cell dataset combining single-cell RNA-seq and proteomic secretome data. The dataset covers over 150,000 cytokine and drug perturbation conditions, aiming to accelerate drug target discovery. Foundational partners include GSK, Pfizer, Sanofi, Graph Therapeutics, and Turbine.LelezardParse Biosciences et Nomic annoncent un jeu de données multimodal de 100 millions de cellules, prêt pour l'IA, dédié à la biologie immunitaireParse Biosciences and Nomic announced a partnership to create Cascade, a multimodal dataset of 100 million cells for immunology research. The dataset combines single-cell RNA sequencing with proteomic secretome data across over 150,000 perturbation conditions. It aims to accelerate drug target discovery and AI-based immune modeling.Business Wire BlogParse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune BiologyParse Biosciences and Nomic announced a partnership to generate Cascade, a 100-million-cell multimodal dataset for immune biology. The dataset combines single-cell RNA-seq with over 11,000 proteomic secretome profiles across 150,000 perturbation conditions. It aims to accelerate drug target discovery and improve AI models for immune response prediction.Business & FinancialParse Biosciences And Nomic Announce 100 Million Cell, Multimodal AI-Ready Dataset For Immune BiologyParse Biosciences and Nomic announced a multimodal dataset combining 100 million single-cell RNA-seq profiles with over 11,000 proteomic secretome profiles for immune biology. The dataset covers responses to over 150,000 cytokine and drug perturbation conditions, aiming to improve AI models for drug discovery.Business Wire BlogParse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater FlexibilityParse Biosciences launched Evercode MAX, a modular single-cell sequencing platform, now shipping to customers. It supports up to 384 samples and 2 million cells, reducing cost per sample by up to 58%. The platform runs on existing v4 chemistry and is available for multiple applications.AETOSWireParse Biosciences and Nomic Announce 100 Million Cell, Multimodal AI-ready Dataset for Immune BiologyParse Biosciences and Nomic Bio announced a partnership to generate Cascade, a 100-million-cell multimodal dataset for immune biology. The dataset combines single-cell RNA-seq and proteomic secretome data across over 150,000 perturbation conditions, with commitments from GSK, Pfizer, and others.AETOSWireGarvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider NetworkGarvan Institute of Medical Research's Genomics Platform has joined Parse Biosciences' Certified Service Provider network, offering Evercode WT single cell sequencing kits across Asia-Pacific. The partnership expands access to high-quality sequencing for researchers in the region.AETOSWireParse Biosciences Launches the Next Generation of its Immune Profiling KitsParse Biosciences launched updated Evercode TCR and BCR kits, shipping worldwide. The kits use v4 chemistry, improving sensitivity and receptor recovery for single-cell immune profiling. The company says the updates will accelerate discovery in autoimmunity and cancer immunotherapy.AETOSWireParse Biosciences Invalidates All 10x Genomics’ Patent Claims Asserted Against Its ProductsThe USPTO's Patent Trial and Appeal Board issued Final Written Decisions invalidating all claims in 10x Genomics' patents asserted against Parse Biosciences' products. The decisions also invalidated a third patent last year, clearing all claims Parse faces. Parse's CEO called the outcome a win for innovation and accessibility.